BVS - Company ID 0001665988
The table below shows Bioventus Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $142.44M | $153.21M | $132.09M | $138.65M | $147.66M | $123.88M |
| Cost of revenue | $45.31M | $47.54M | $41.32M | $44.42M | $45.57M | $40.82M |
| Gross profit | $97.13M | $105.67M | $90.77M | $94.23M | $102.09M | $83.06M |
| R&D | $3.44M | $3.17M | $2.47M | $2.92M | $3.17M | $3.01M |
Bioventus Inc. reported annual revenue of $568.09M for fiscal year 2025. That is down 0.9% from $573.28M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $340.14M (FY 2019) to $568.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $82.94M | $82.74M | $78.33M | $78.66M | $79.11M | $73.50M |
| Operating income | $9.70M | $19.13M | $8.42M | $11.25M | $18.37M | $4.87M |
| Income tax | -$701.00K | -$20.90M | $571.00K | $664.00K | $1.04M | -$95.00K |
| Net income | $5.99M | $33.44M | $3.11M | $3.15M | $7.46M | -$2.64M |
| EPS (diluted) | $0.08 | $0.47 | $0.04 | $0.05 | $0.11 | -$0.04 |